Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
ACS Medicinal Chemistry Letters|October 18, 2023
A Novel 7<i>H</i>-[1,2,4]Triazolo[3,4-<i>b</i>]thiadiazine-based Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Directed toward Treatment of Cystic FibrosisAndras Rab, Xun Yang, William F Tracy, et al.
The Journal of Biological Chemistry|October 5, 2007
Molecular proximity of cystic fibrosis transmembrane conductance regulator and epithelial sodium channel assessed by fluorescence resonance energy transferBakhrom K Berdiev, Estelle Cormet-Boyaka, Albert Tousson, et al.
Cancer Research|September 18, 2004
Excellent in vivo bystander activity of fludarabine phosphate against human glioma xenografts that express the escherichia coli purine nucleoside phosphorylase geneJeong S Hong, William R Waud, Dana N Levasseur, et al.
Human Gene Therapy|April 7, 2005
Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapySuman Bharara, Eric J Sorscher, G Yancey Gillespie, et al.
JCI Insight|May 22, 2026
Broadening activity of checkpoint blockade agents by intratumoral nucleoside cleavageRegina Rab, Jeong S Hong, Brendan Lc Kinney, et al.
The Journal of Clinical Investigation|October 29, 2019
Slowing ribosome velocity restores folding and function of mutant CFTRKathryn E Oliver, Robert Rauscher, Marjolein Mijnders, et al.
JCI Insight|July 27, 2018
Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulatorsSangwoo T Han, Andras Rab, Matthew J Pellicore, et al.
Chemistry & Biology|January 1, 2004
Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug systemEric M Bennett, Ruchi Anand, Paula W Allan, et al.
American Journal of Respiratory and Critical Care Medicine|April 23, 2016
Discovery of Clinically Approved Agents That Promote Suppression of Cystic Fibrosis Transmembrane Conductance Regulator Nonsense MutationsVenkateshwar Mutyam, Ming Du, Xiaojiao Xue, et al.
Plos One|February 14, 2025
Evaluating elexacaftor/tezacaftor/ivacaftor (ETI; Trikafta™) for treatment of patients with non-cystic fibrosis bronchiectasis (NCFBE): A clinical study protocolColin E Swenson, William R Hunt, Candela Manfredi, et al.
Pageof 5